| Affiliation: | 1.Vaccines Division,National Institute of Food and Drug Safety Evaluation,Cheongju-si,Republic of Korea;2.Department of Biochemistry, College of Natural Sciences,Chungbuk National University,Cheongju-si,Republic of Korea;3.Biologics Division,National Institute of Food and Drug Safety Evaluation,Cheongju-si,Republic of Korea |
| Abstract: | ![]()
ObjectivesThe single radial immunodiffusion (SRID) assay, used to quantify hemagglutinin (HA) in influenza vaccines, requires reference reagents; however, because centralized production of reference reagents may slow the emergency deployment of vaccines, alternatives are needed.ResultsWe investigated the production of HA proteins using recombinant DNA technology, rather than a traditional egg-based production process. The HA proteins were then used in an SRID assay as a reference antigen. We found that HA can be quantified in both egg-based and cell-based influenza vaccines when recombinant HAs (rHAs) are used as the reference antigen. Furthermore, we confirmed that rHAs obtained from strains with pandemic potential, such as H5N1, H7N3, H7N9, and H9N2 strains, can be utilized in the SRID assay. The rHA production process takes just one month, in contrast to the traditional process that takes three to four months.ConclusionsThe use of rHAs may reduce the time required to produce reference reagents and facilitate timely introduction of vaccines during emergencies. |
